US Liquid Biopsy Market Research Report Information By Biomarker Types (Circulating Tumor Cells, Circulating Tumor DNA, Extracellular Vesicles, and Other Biomarker), By Application (Cancer Therapeutic Application, Reproductive Health, and Other Therapeutic), By Sample (Blood Sample, Urine Sample, and Other), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

In 2016, the United States dominated the market with a substantial share of 85.01%, and this dominance is expected to continue with a projected Compound Annual Growth Rate (CAGR) of 29% from 2016 to 2022. Simultaneously, Canada is emerging as the fastest-growing market, poised to experience a CAGR of 25.4% during the same forecast period.

Among the various components, Circulating Tumor Cells (CTCs) held the largest market share in 2016, accounting for 55.49%. This segment is anticipated to maintain its lead with a CAGR of 28.5% from 2016 to 2022. Notably, Circulating Tumor DNA (CtDNA) is the fastest-growing market within this domain, expected to exhibit a robust CAGR of 29.6%.

Cancer-related applications constituted the largest market share in 2016 at 84.75%, with an anticipated growth rate of 28.6% during the forecast period. Remarkably, the market for reproductive health is exhibiting remarkable growth, projected to achieve a CAGR of 29.3%.

In terms of sample types, blood samples dominated the market in 2016, capturing a significant share of 88.71%. The dominance of blood samples is expected to persist, with a projected CAGR of 28.6% from 2016 to 2022. Conversely, the urine sample market is emerging as the fastest-growing segment, anticipated to grow at a robust CAGR of 29.3%.

Examining market distribution channels, hospitals and laboratories held the lion's share in 2016, accounting for 45.31%. This segment is poised for continued growth with an expected CAGR of 28.9% during the forecast period. On the other hand, academic and research centers are identified as the fastest-growing market in this category, projected to experience a CAGR of 28.7%.

When focusing specifically on the breakdown between Circulating Tumor Cells (CTCs) and Circulating Tumor DNA (CtDNA), the former accounted for a significant market share of 55.03% in 2016. Projections indicate a continued lead with an anticipated CAGR of 29.1%. Notably, Circulating Tumor DNA (CtDNA) is the fastest-growing market within this segment, expected to grow at an impressive CAGR of 30.0%.

Considering the sample types within this context, cancer-related applications continued to dominate the market in 2016, capturing a substantial share of 85.07%. This trend is expected to persist with a projected CAGR of 29.1%. Concurrently, reproductive health applications are emerging as the fastest-growing market within this category, anticipated to achieve a noteworthy CAGR of 29.9%.

In summary, the data highlights the dominance of the United States in this market, with Canada emerging as a rapidly growing player. Circulating Tumor Cells (CTCs), cancer-related applications, blood samples, and hospital/laboratory distribution channels continue to play pivotal roles, while notable growth is observed in emerging segments such as reproductive health, urine samples, and academic/research centers. These trends underscore the dynamic and evolving nature of the liquid biopsy market, with diverse applications and channels contributing to its overall growth.